The therapeutic effect of inflammatory bowel disease has improved in the past decades, but most of patients cannot tolerate, do not respond to drugs, or relapse after treating with conventional therapy. Therefore, new and more effective treatment methods are still needed in treatment of IBD. In this review, we will discuss the relevant mechanisms and the latest research progress of biologics (anti-TNF treatments, interleukin inhibitors, integrin inhibitors, antisense oligonucleotide, and JAK inhibitors) for IBD, focus on the efficacy and safety of drugs for moderate-to-severe IBD, and summarize the clinical status and future development direction of biologics in IBD.

炎症性肠病的治疗效果在过去几十年有所改善，但大多数患者不能耐受，对药物无反应，或在常规治疗后复发。因此，IBD的治疗仍需要新的、更有效的治疗方法。在本综述中，我们将讨论生物制剂（抗 TNF 治疗、白介素抑制剂、整合素抑制剂、反义寡核苷酸和 JAK 抑制剂）治疗 IBD 的相关机制和最新研究进展，重点关注药物治疗中度的疗效和安全性。对重症IBD，并总结IBD生物制剂的临床现状和未来发展方向。